GEN sat down with Marcos Milla, PhD, chief scientific officer, and Lauren Baker, VP of Scientific & Medical Affairs, to discuss the history and future direction of Synthorx’s Expanded Genetic Alphabet platform technology. We also covered the company’s development since its recent acquisition by Sanofi . . .
X and Y: Synthorx Expands the Genetic Code to Create Optimized Biologics
Source: ktsdesign/Fotolia